Woods Matthew T, Brown Peter A, Baig-Lewis Shahana F, Simpson Eric L
Oregon Health & Science University, Department of Dermatology, Portland, OR 97239-4501, USA.
J Drugs Dermatol. 2011 Feb;10(2):171-6.
To determine the effect a novel formulation of fluocinonide cream on skin barrier function in subjects with atopic dermatitis.
The authors performed an open-label, investigator-blinded, side-by-side, controlled trial examining skin barrier function before and after a two-week course of a class I, super-potent topical steroid.
Outpatient university-based dermatology clinic in Portland, OR.
Twenty-five subjects aged 12 or older with a diagnosis of moderate, severe, or very severe AD were recruited for this study.
Fluocinonide 0.1% cream, a novel formulation of a class I super-potent topical steroid was applied to all affected areas, except a control site, once daily for two weeks or until clear. The control target site was treated with the vehicle once daily.
MAIN OUTCOME MEASURE(S): The study's primary outcome was change in skin barrier function as measured by basal transepidermal water loss (TEWL) in acute lesional skin from baseline as measured at two weeks.
TEWL readings significantly decreased (reflecting improved barrier function) in both the active and control target sites. The active target site decreased 14.35+/-16 mg/cm2 per hour; 95 percent confidence interval, P<0.001. The control target site decreased 8.75+/-11.80 mg/cm2 per hour in 25 subjects; 95 percent confidence interval, P<0.001. Skin electrical capacitance also improved significantly, reflecting improved stratum corneum hydration with therapy. Pruritus, clinical severity, and quality of life scores all showed significant improvement by the end of the study.
The authors have shown that short-term treatment with a novel formulation of 0.1% fluocinonide led to significantly improved barrier function as measured by basal TEWL in subjects with active moderate to severe AD. These data suggest short-term treatment with AD with a super-potent corticosteroid improves skin barrier function.
确定一种新剂型的氟轻松乳膏对特应性皮炎患者皮肤屏障功能的影响。
作者进行了一项开放标签、研究者设盲、并排对照试验，在给予I类超强效外用类固醇药物两周疗程前后检查皮肤屏障功能。
俄勒冈州波特兰市的大学门诊皮肤科诊所。
招募了25名年龄在12岁及以上、诊断为中度、重度或极重度特应性皮炎的受试者参与本研究。
将0.1%氟轻松乳膏（一种新剂型的I类超强效外用类固醇）每天一次涂抹于所有受累部位，但不包括对照部位，持续两周或直至皮损消退。对照目标部位每天一次使用赋形剂治疗。
研究的主要观察指标是通过测量急性皮损皮肤的基础经表皮水分流失（TEWL）来评估皮肤屏障功能从基线到两周时的变化。
活性部位和对照目标部位的TEWL读数均显著降低（反映屏障功能改善）。活性目标部位每小时降低14.35±16mg/cm²；95%置信区间，P<0.001。25名受试者的对照目标部位每小时降低8.75±11.80mg/cm²；95%置信区间，P<0.001。皮肤电容也显著改善，反映出治疗后角质层水合作用增强。瘙痒、临床严重程度和生活质量评分在研究结束时均显示出显著改善。
作者表明，对于患有活动性中度至重度特应性皮炎的受试者，用0.1%氟轻松新剂型进行短期治疗可使基础TEWL测量的屏障功能显著改善。这些数据表明，用超强效皮质类固醇对特应性皮炎进行短期治疗可改善皮肤屏障功能。
